This study reported three related cases of woollyhairsyndrome transmitted as a dominant autosomal trait, characterized by fine, frizzy hair and general hair thinning.
This case series describes eight instances of autosomal recessive woollyhair in an Indian population over the past 12 years, detailing their clinical presentation, hair traits, and treatment response.
This study reviewed the medical literature on generalized woollyhair and reported that while there are no effective treatments, some narratives suggest that topical Minoxidil may help with hypotrichosis associated with the condition.
PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.
Hair regrowth treatments are effective in mice but not yet available for humans. The discussion humorously highlights frustration over this disparity and mentions a project to genetically modify elephants to resemble mammoths.
PP405 shows promise for hair growth but may need continuous use like Minoxidil. Current treatments include Minoxidil, finasteride, and dutasteride, with skepticism about a true cure due to financial interests.
A 30-year-old male saw significant hair regrowth after 8 months using minoxidil, finasteride, microneedling, and Nizoral shampoo. He experienced no side effects from finasteride and credited his success to this regimen.
Subcutaneous scalp fat may be linked to hair loss, with theories suggesting that fat loss can lead to reduced blood flow and increased DHT activity, contributing to hair loss. Treatments discussed include PRP/PRF injections and fat transfer to improve scalp thickness and blood flow.